Swiss National Bank Acquires 1,300 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Swiss National Bank grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.0% in the fourth quarter, Holdings Channel reports. The firm owned 136,654 shares of the medical equipment provider’s stock after buying an additional 1,300 shares during the quarter. Swiss National Bank’s holdings in Lantheus were worth $12,225,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. State of New Jersey Common Pension Fund D boosted its position in shares of Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after buying an additional 115 shares during the last quarter. Bleakley Financial Group LLC boosted its holdings in shares of Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after acquiring an additional 129 shares during the last quarter. Avantax Advisory Services Inc. grew its stake in shares of Lantheus by 5.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 132 shares during the period. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in Lantheus by 0.9% during the fourth quarter. Arizona State Retirement System now owns 20,137 shares of the medical equipment provider’s stock valued at $1,801,000 after purchasing an additional 178 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 1.0 %

LNTH stock opened at $103.28 on Thursday. The business’s 50-day moving average price is $92.54 and its 200-day moving average price is $96.68. The stock has a market cap of $7.07 billion, a P/E ratio of 17.18 and a beta of 0.38. Lantheus Holdings, Inc. has a twelve month low of $57.78 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of research analyst reports. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. Truist Financial upped their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.